LGR6 is a prognostic biomarker for less differentiated tumors in lymph nodes of colon cancer patients
(2024) In Frontiers in Oncology 14.- Abstract
Introduction: The aim was to investigate whether the stem cell marker LGR6 has prognostic value in colon cancer, alone or in combination with the prognostic biomarkers CEA and CXCL16. Methods: LGR6 mRNA levels were determined in 370 half lymph nodes of 121 colon cancer patients. Ability to predict relapse after curative surgery was estimated by Kaplan-Meier survival model and Cox regression analyses. Results: Patients with high LGR6 levels [LGR6(+)] had a decreased mean survival time of 11 months at 5-year follow-up and 47 months at 12-year follow-up, respectively, with hazard ratios of 3.2 and 2.8. LGR6 mRNA analysis added prognostic value to CEA and CXCL16 mRNA analysis. In the poor prognosis groups CEA(+) and CXCL16(+), further... (More)
Introduction: The aim was to investigate whether the stem cell marker LGR6 has prognostic value in colon cancer, alone or in combination with the prognostic biomarkers CEA and CXCL16. Methods: LGR6 mRNA levels were determined in 370 half lymph nodes of 121 colon cancer patients. Ability to predict relapse after curative surgery was estimated by Kaplan-Meier survival model and Cox regression analyses. Results: Patients with high LGR6 levels [LGR6(+)] had a decreased mean survival time of 11 months at 5-year follow-up and 47 months at 12-year follow-up, respectively, with hazard ratios of 3.2 and 2.8. LGR6 mRNA analysis added prognostic value to CEA and CXCL16 mRNA analysis. In the poor prognosis groups CEA(+) and CXCL16(+), further division was achieved by LGR6 analysis. LGR6(+) patients had a very poor prognosis. LGR6 also identified a small number of CEA(-), TNM stage I patients who relapsed suggesting stem cell origin of these tumors. LGR6 and LGR5 levels correlated strongly in lymph nodes of stage I and IV patients but not in stage II patients, suggesting that these stem cell markers are differentially regulated. Conclusion: This study highlights LGR6 as a useful prognostic biomarker independently and in combination with CEA, CXCL16 or LGR5 identifying different risk groups.
(Less)
- author
- Eltorky, Hagar ; AbdelMageed, Manar ; Ismail, Hager ; Zahran, Faten ; Guirgis, Adel ; Olsson, Lina ; Lindmark, Gudrun LU ; Hammarström, Marie Louise ; Hammarström, Sten and Sitohy, Basel
- organization
- publishing date
- 2024
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- cancer stem cells, CEA, colon cancer, CXCL16, LGR5, LGR6, qRT-PCR, regional lymph nodes
- in
- Frontiers in Oncology
- volume
- 14
- article number
- 1393075
- publisher
- Frontiers Media S. A.
- external identifiers
-
- scopus:85192206246
- pmid:38715790
- ISSN
- 2234-943X
- DOI
- 10.3389/fonc.2024.1393075
- language
- English
- LU publication?
- yes
- id
- c39e5e21-bd52-448b-a63d-81abec8b0500
- date added to LUP
- 2024-05-16 14:22:14
- date last changed
- 2024-08-23 00:05:03
@article{c39e5e21-bd52-448b-a63d-81abec8b0500, abstract = {{<p>Introduction: The aim was to investigate whether the stem cell marker LGR6 has prognostic value in colon cancer, alone or in combination with the prognostic biomarkers CEA and CXCL16. Methods: LGR6 mRNA levels were determined in 370 half lymph nodes of 121 colon cancer patients. Ability to predict relapse after curative surgery was estimated by Kaplan-Meier survival model and Cox regression analyses. Results: Patients with high LGR6 levels [LGR6(+)] had a decreased mean survival time of 11 months at 5-year follow-up and 47 months at 12-year follow-up, respectively, with hazard ratios of 3.2 and 2.8. LGR6 mRNA analysis added prognostic value to CEA and CXCL16 mRNA analysis. In the poor prognosis groups CEA(+) and CXCL16(+), further division was achieved by LGR6 analysis. LGR6(+) patients had a very poor prognosis. LGR6 also identified a small number of CEA(-), TNM stage I patients who relapsed suggesting stem cell origin of these tumors. LGR6 and LGR5 levels correlated strongly in lymph nodes of stage I and IV patients but not in stage II patients, suggesting that these stem cell markers are differentially regulated. Conclusion: This study highlights LGR6 as a useful prognostic biomarker independently and in combination with CEA, CXCL16 or LGR5 identifying different risk groups.</p>}}, author = {{Eltorky, Hagar and AbdelMageed, Manar and Ismail, Hager and Zahran, Faten and Guirgis, Adel and Olsson, Lina and Lindmark, Gudrun and Hammarström, Marie Louise and Hammarström, Sten and Sitohy, Basel}}, issn = {{2234-943X}}, keywords = {{cancer stem cells; CEA; colon cancer; CXCL16; LGR5; LGR6; qRT-PCR; regional lymph nodes}}, language = {{eng}}, publisher = {{Frontiers Media S. A.}}, series = {{Frontiers in Oncology}}, title = {{LGR6 is a prognostic biomarker for less differentiated tumors in lymph nodes of colon cancer patients}}, url = {{http://dx.doi.org/10.3389/fonc.2024.1393075}}, doi = {{10.3389/fonc.2024.1393075}}, volume = {{14}}, year = {{2024}}, }